AstraZeneca reported second-quarter results on Monday that topped profit expectations, with the Anglo-Swedish pharmaceutical company holding its 2026 guidance and $80 billion annual revenue target for 2030.
Core earnings per share reached $2.63 for the three months ended June 30, a gain of 18% on a constant-currency basis
Total revenue rose 5% to $15.38 billion. Analyst consensus had expected core EPS of $2.48 and revenue of $15.39 billion, according to Reuters. Net profit climbed more than 2% to $2.51 billion compared with the same period a year earlier, the company said.
Cancer drug sales climbed 15% and rare disease revenues were up 8%, while China, AstraZeneca’s second-largest market, saw a 13% revenue decline as generic competition and policy shifts weighed on results. For the full year 2026, AstraZeneca maintained its forecast of low double-digit percentage growth in core earnings per share at constant currency, alongside total revenue growth in the mid-to-high-single-digit range. “We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months,” CEO Pascal Soriot said in a statement. Soriot also told journalists the company was building toward its 2030 revenue ambition and beyond. “We have the science, we have the pipeline, and we have the team to make this happen,” he said, according to Reuters.